<DOC>
	<DOCNO>NCT02290106</DOCNO>
	<brief_summary>HMG co-A reductase inhibitor , commonly call statin , effective treatment dyslipidemia atherosclerotic heart disease proven mortality benefit . While lipid-lowering effect statins well-known , metabolic effect , include effect glucose tolerance ectopic fat distribution , less completely understood . Recent study show statin may increase risk diabetes . Further , research suggest statin may benefit nonalcoholic fatty liver disease ( NAFLD ) , condition associate obesity include increase fat liver ( steatosis ) , case , inflammation hepatocellular damage ( steatohepatitis ) . Pitavastatin , approve United States Food Drug Administration ( FDA ) 2009 , recent statin enter market . Unlike statin , pitavastatin primarily metabolize cytochrome P450 ( CYP450 ) , thus reduce potential interaction medication metabolize CYP450 . Previous study suggest pitavastatin may neutral glucose homeostasis may improve hepatic lipid . Neither effect proven definitively , however , current proposal aim characterize detail effect pitavastatin glucose homeostasis , hepatic steatosis , steatohepatitis .</brief_summary>
	<brief_title>Effects Pitavastatin Insulin Sensitivity Liver Fat</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>1 . Men age 4065yo 2 . BMI ≥ 27kg/m2 waist circumference ≥102cm , high probability risk factor NAFLD 3 . At least one follow indicate insulin resistance : Fasting glucose ≥100mg/dL &lt; 126mg/dL , HOMAIR &gt; 2.0 , and/or 2 hour glucose ≥140mg/dL &lt; 200mg/dL follow standard glucose tolerance test . 4 . 10year cardiovascular disease risk ≥5 % American Heart Association ( AHA ) /American College Cardiology ( ACC ) Pooled Cohort Equations CV Risk Calculator LDL ≥ 100mg/dL 5 . No use statin within 1 year study entry actively consider statin therapy treat provider . 1 . Diagnosis diabetes use antidiabetic medication . 2 . Use erythromycin , rifampin , cyclosporin , colchicine , gemfibrozil . 3 . Use statin therapy within 1 year prior study entry . Use lipidmodifying therapy ( include fish oil , fibrates , niacin , gemfibrozil ) within 6 month study entry . 4 . Contraindication statin therapy . 5 . Creatinine &gt; upper limit normal know renal disease 6 . AST ALT &gt; 3 time upper limit normal 7. hemoglobin &lt; 10g/dL 8 . Contraindication undergo magnetic resonance scan . 9 . Atherosclerotic cardiovascular disease lowdensity lipoprotein cholesterol ( LDLC ) ≥ 190mg/dL . 10 . Triglyceride ≥500mg/dL</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>obesity</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>statin ( HMG-CoA Reductase Inhibitor )</keyword>
	<keyword>fatty liver</keyword>
</DOC>